878 results on '"Attarian, Shahram"'
Search Results
2. Clinical, paraclinical and outcome features of 166 patients with acute anti-GQ1b antibody syndrome
3. Real-world data of in-hospital administration of alglucosidase alfa in French patients with Pompe disease: results from the National Claims Database
4. French National Protocol for diagnosis and care of facioscapulohumeral muscular dystrophy (FSHD)
5. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy
6. Clinical and genetic features of patients suffering from CMT4J
7. Face to Face: deciphering facial involvement in inclusion body myositis
8. Association between brain and upper cervical spinal cord atrophy assessed by MRI and disease aggressiveness in amyotrophic lateral sclerosis
9. Could the motor unit number index be an early prognostic biomarker for amyotrophic lateral sclerosis?
10. Caffeine consumption outcomes on amyotrophic lateral sclerosis disease progression and cognition
11. Association of Plasma Creatinine Phosphokinase Elevation and a History of Idiopathic Cardiomyopathy in Recipients of Heart Transplant
12. Transthyretin amyloid cardiomyopathy in France: A cross-sectional multi-centre study (333 patients)
13. Dépistage génétique néonatal : à propos du programme pilote sur l’amyotrophie spinale (DEPISMA)
14. Correction to: A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
15. Multidisciplinary team meetings in treatment of spinal muscular atrophy adult patients: a real-life observatory for innovative treatments
16. Functional and Molecular Characterization of New SPTLC1 Missense Variants in Patients with Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)
17. One-Year Longitudinal Assessment of Patients With CMT1A Using Quantitative MRI
18. Itinéraire, prise en charge et pronostic des encéphalites au centre hospitalier d’Aix-en-Provence : étude rétrospective sur 5 ans
19. Profils clinique, électrophysiologique et biologique des neuropathies anti-MAG en fonction du statut mutationnel MYD88 et de l’hémopathie sous-jacente
20. Évaluation longitudinale de patients CMT1A sur 1 an : apport de l’IRM neuromusculaire quantifiée
21. Quel est le meilleur biomarqueur électrophysiologique pour le suivi des porteurs asymptomatiques d’une mutation dans le gène de la transthyrétine ?
22. Corrélation phénotype-génotype dans la maladie de Charcot-Marie-Tooth liée à l’X : une étude de cohorte française
23. Facteurs affectant la présentation clinique des complications neurologiques en lien avec la consommation de protoxyde d’azote : moelle ou nerf ?
24. Monitoring des effets à court terme des immunoglobulines intraveineuses dans la PIDC : quels sont les biomarqueurs les plus pertinents ?
25. Dystrophies musculaires des ceintures associées aux mutations de TRIM32 : cohorte française et revue de la littérature
26. Neurofilament Light Chain Levels Interact with Neurodegenerative Patterns and Motor Neuron Dysfunction in Amyotrophic Lateral Sclerosis
27. Factors affecting the topography of nitrous oxide‐induced neurological complications
28. Post-hoc Nonparametric Analysis of Forced Vital Capacity in the COMET Trial Demonstrates Superiority of Avalglucosidase Alfa vs Alglucosidase Alfa
29. Expanding the importance of HMERF titinopathy: new mutations and clinical aspects
30. Longitudinal follow‐up and prognostic factors in nitrous oxide‐induced neuropathy.
31. Safety and efficacy of cipaglucosidase alfa plus miglustat versus alglucosidase alfa plus placebo in late-onset Pompe disease (PROPEL): an international, randomised, double-blind, parallel-group, phase 3 trial
32. Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial
33. Reply to letter on What biological markers could be used for diagnosis and monitoring of nitrous oxide abuse
34. Retrospective clinical and genetic analysis of COL6-RD patients with a long-term follow-up at a single French center
35. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial
36. Patient-Reported Symptom Burden of Charcot–Marie–Tooth Disease Type 1A: Findings From an Observational Digital Lifestyle Study
37. Long-term safety and efficacy of patisiran for hereditary transthyretin-mediated amyloidosis with polyneuropathy: 12-month results of an open-label extension study
38. Electrodiagnostic subtyping in Guillain–Barré syndrome patients in the International Guillain–Barré Outcome Study.
39. Predicting Outcome in Guillain-Barré Syndrome: International Validation of the Modified Erasmus GBS Outcome Score
40. Motor unit number index as an individual biomarker: Reference limits of intra-individual variability over time in healthy subjects
41. Clinical, biological, electrophysiological and therapeutic profile of patients with anti-MAG neuropathy according to MYD88L265P and CXCR4 mutations and underlying haemopathy.
42. Antibodies against the node of Ranvier: a real-life evaluation of incidence, clinical features and response to treatment based on a prospective analysis of 1500 sera
43. A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases
44. Combination of serum and CSF neurofilament-light and neuroinflammatory biomarkers to evaluate ALS
45. A double-blind, placebo-controlled, randomized trial of PXT3003 for the treatment of Charcot–Marie–Tooth type 1A
46. Electrophysiological features of chronic inflammatory demyelinating polyradiculoneuropathy associated with IgG4 antibodies targeting neurofascin 155 or contactin 1 glycoproteins
47. Clinical and genetic features of patients suffering from CMT4J
48. The Impact of Fatty Infiltration on MRI Segmentation of Lower Limb Muscles in Neuromuscular Diseases: A Comparative Study of Deep Learning Approaches
49. ConText-GAN: using contextual texture information for realistic and controllable medical image synthesis*
50. European Academy of Neurology/Peripheral Nerve Society Guideline on diagnosis and treatment of Guillain–Barré syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.